Swedish-Nature-25-1248x672

AAV Total Antibody Assessment

Reliable Detection of Total Antibodies against AAV capsids.

gene therapy

AAV Total Antibody Assessment

AAV Total Antibody Assessment

In gene therapy, managing immunogenicity is critical – yet designing AAV capsids that evade immune detection remains a major challenge. The right analytical tools can help you optimize vector design, enhance safety, and maximize therapeutic efficacy.

Simplicity Meets Flexibility

Our customizable ELISA-based AAV Total Antibody (TAb) assay enables accurate, efficient, and routine monitoring of immune responses against AAV capsids.

The two-step AAV TAb ELISA quantifies total antibody binding to AAV vectors across serotypes—including your custom capsids—using your own AAV prep. No surrogate vector required.

  • Customizable for Any Capsid – Adapt the assay to any AAV serotype, hybrid, or chimeric vector for next-gen development.
  • Robust & Reliable – ELISA-based detection ensures sensitive, reproducible results across diverse sample types.
  • Proven Quality – Built on decades of immunoassay expertise, delivering trusted performance and consistency.

Our AAV Total Antibody Assay

Didn't find what you were looking for?

We offer products customized to your needs. Our custom iLite® reporter-gene assays can be adapted to almost any target. We also offer custom ELISA plates and other products. In addition, you can take advantage of our service offerings and let us do the work for you.

Contact Us

How it works

ELISA plate coated with immobilized vector

1. ELISA plate coated with immobilized vector

Wild-type vectors or your custom vector can be used.

Capture of Anti-AAV Binders

2. Capture of Anti-AAV Binders

Anti-AAV antibodies and potential complement activators (e.g., immunoglobulins/C1q, MBL/ficolins, and C3b) are captured from a human serum sample under complement-suppressing conditions.

Complement activation

3. Complement activation

Following a washing step, the serum sample is reapplied in a complement-permissive buffer. If complement-activating binders are present, terminal pathway activity results in TCC deposition.

Detection

4. Detection

Detection is performed using an anti-TCC antibody, generating a signal proportional to the level of complement activation.

Contact our gene therapy team

Write us a message and a product specialist will get in touch